Modulating viscosity improves lentiviral transduction of NK cells: A simple solution to a persistent problem

Area of Science:

• Biotechnology
• Immunotherapy
• Cellular Engineering

Background:

• Genetically modified cell therapies (GMCT) show promise for treating various diseases.
• Low transduction efficiency, especially in primary cells like NK cells, hinders GMCT development.
• High cost and manufacturing complexity are significant barriers to widespread GMCT adoption.

Purpose of the Study:

• To develop a cost-effective and GMP-compatible solution to improve genetic modification efficiency in immune cells.
• To evaluate the efficacy of a novel viscous transduction medium (VTM) for enhancing transduction rates.
• To assess the impact of VTM on cell viability, expansion, and function.

Main Methods:

• Development of a modified viscous transduction medium (VTM) using methyl-cellulose.
• Transduction of primary human natural killer (NK) cells, T cells, and hematopoietic stem cells using VTM.
• Comparison of VTM with commercially available transduction enhancers.
• Assessment of cell viability, expansion, function, and yield post-transduction.

Main Results:

• VTM significantly increased transduction efficiency in primary human NK cells without compromising viability, expansion, or function.
• VTM outperformed existing commercial transduction enhancers.
• Transduction with VTM led to a significant improvement in the yield of anti-CD22 chimeric antigen receptor (CAR)-NK cells.
• VTM demonstrated effectiveness in improving transduction of primary T cells and hematopoietic stem cells.

Conclusions:

• VTM offers a simple, cost-effective, and GMP-compliant method to enhance the yield of genetically modified immune cells.
• This approach has the potential to improve immunotherapy efficacy and reduce production costs.
• VTM represents a promising advancement for the manufacturing of cell-based therapies.